Your browser doesn't support javascript.
Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China.
Ma, Yiming; Zeng, Huihui; Zhan, Zijie; Lu, Huanhuan; Zeng, Zihang; He, Chenjie; Liu, Xiangming; Chen, Chen; Qin, Qingwu; He, Jia; Zhou, Zhiguo; Huang, Peng; Jiang, Mingyan; Deng, Dingding; Liao, Xin; Xiang, Zhi; Huang, Xiaoying; Chen, Yan; Chen, Ping.
  • Ma Y; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zeng H; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zhan Z; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Lu H; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zeng Z; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • He C; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Liu X; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Chen C; Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Qin Q; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • He J; Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zhou Z; Department of Respiratory Medicine, The First Hospital of Changsha, Changsha, China.
  • Huang P; Department of Respiratory Medicine, Zhuzhou Central Hospital, Zhuzhou, China.
  • Jiang M; Department of Respiratory and Critical Medicine, Xiangtan Central Hospital, Xiangtan, China.
  • Deng D; Department of Respiratory Medicine, The First Affiliated Hospital of Shaoyang University, Shaoyang, China.
  • Liao X; Department of Respiratory Medicine, The Central Hospital of Shaoyang, Shaoyang, China.
  • Xiang Z; Department of Respiratory Medicine, Huaihua First People's Hospital, Huaihua, China.
  • Huang X; Department of Respiratory Medicine, Loudi Central Hospital, Loudi, China.
  • Chen Y; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Chen P; Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Front Pharmacol ; 11: 1198, 2020.
Article in English | MEDLINE | ID: covidwho-742738
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) has developed into a worldwide pandemic. This study aimed to retrospectively describe the use of corticosteroids in treating COVID-19.

METHODS:

For this multicenter retrospective study, medical records from 488 symptomatic COVID-19 patients were reviewed. Patients were divided into severe and nonsevere groups. Baseline characteristics, signs and symptoms, laboratory findings, treatments, and disease outcomes were compared. Specific data for corticosteroid treatment were further analyzed.

RESULTS:

Four hundred fifty COVID-19 patients were included in this study, including 82 severe patients and 368 nonsevere cases. Out of the 450 patients, 126 (28.0%) received corticosteroid treatment. In the 126 patients treated with corticosteroids, the median daily dose of corticosteroid therapy was 56.6 [interquartile range (IQR) 40.0-78.4] mg and median corticosteroid therapy duration was 5.0 (IQR 3.0-7.0) days. Among nonsevere cases, patients treated with corticosteroids were significantly older in comparison with patients who did not receive corticosteroid treatment (p<0.01); the proportion of patients receiving antibiotic therapy in the corticosteroid group was significantly higher than that in the noncorticosteroid group (p<0.001); hospitalization length and duration of viral shedding were significantly longer in patients in the corticosteroid group than in the noncorticosteroid group after adjusting for age, sex, and comorbidities (p<0.05). In severe cases, patients treated with corticosteroids were significantly older and comorbidities at admission were significantly more common in patients receiving corticosteroid treatment (p<0.05); the proportion of patients receiving antibiotic therapy in the corticosteroid group was significantly higher than that in the noncorticosteroid group (p<0.001); no significant difference in hospitalization length or viral shedding duration was found between two groups after adjusting for age, sex, and comorbidities (p>0.05).

CONCLUSION:

Our study indicates that corticosteroids are regarded as one of treatments in the general clinical practice of COVID-19. However, corticosteroid use may be accompanied by increased use of antibiotics, longer hospitalization, and prolonged viral shedding.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.01198

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Language: English Journal: Front Pharmacol Year: 2020 Document Type: Article Affiliation country: Fphar.2020.01198